Guardant Health, Inc. - Common Stock (NQ:GH)

163.01 +0.02 (+0.01%)

Delayed Quote Updated: 9:47 AM EDT, Oct 15, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Guardant Health, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Guardant Health Shield Blood Test Demonstrates Leading Screening Adherence and CRC Deaths Averted Compared to Stool-Based Tests

Today 8:05 EDT

From Guardant Health, Inc.

Via Business Wire

Guardant Health Announces Approval in Europe of Guardant360® CDx as Companion Diagnostic for AstraZeneca’s ETCAMAH™ (camizestrant) in Advanced ER-positive Breast Cancer

October 08, 2026

From Guardant Health, Inc.

Via Business Wire

Guardant Health to Report Third Quarter 2026 Financial Results on November 5, 2026

October 08, 2026

From Guardant Health, Inc.

Via Business Wire

Guardant Health COSMOS Study Published in Cancer Research Communications Validates Utility of Guardant Reveal™ Liquid Biopsy Test for Predicting Recurrence in Melanoma

October 05, 2026

From Guardant Health, Inc.

Via Business Wire

Guardant Health’s Shield Blood Test Covered by EviCore by Evernorth for Colorectal Cancer Screening

September 14, 2026

From Guardant Health, Inc.

Via Business Wire

Guardant Health and Collaborators to Present 20 Abstracts Highlighting Portfolio of Liquid Biopsy Tests for Early Detection and Ongoing Treatment Management at 2026 World Conference on Lung Cancer

September 09, 2026

From Guardant Health, Inc.

Via Business Wire

Business Insider Names Guardant Health One of America's Most Innovative Businesses

September 08, 2026

From Guardant Health, Inc.

Via Business Wire

Guardant Health Announces Landmark FDA Approval of Guardant360® CDx as Companion Diagnostic for AstraZeneca’s ETCAMAH™ (camizestrant) in Advanced Breast Cancer

September 04, 2026

From Guardant Health, Inc.

Via Business Wire

Guardant Health’s Shield Blood Test Covered by Carelon Health Services for Colorectal Cancer Screening

September 01, 2026

From Guardant Health, Inc.

Via Business Wire

Guardant Health to Appeal Federal District Court Judgment

August 24, 2026

From Guardant Health, Inc.

Via Business Wire

Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 10, 2026

From Guardant Health, Inc.

Via Business Wire

Guardant Health Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance

July 30, 2026

From Guardant Health, Inc.

Via Business Wire

Guardant Health to Participate in Upcoming Investor Conferences

July 29, 2026

From Guardant Health, Inc.

Via Business Wire

Actor and Cancer Advocate Patrick Dempsey Stars in Emotional Tribute Video From Guardant Health Memorializing Those Who Have Lost Their Lives to Colorectal Cancer

July 28, 2026

From Guardant Health, Inc.

Via Business Wire

Guardant Health to Report Second Quarter 2026 Financial Results on July 30, 2026

July 09, 2026

From Guardant Health, Inc.

Via Business Wire

UnitedHealth Group Now Covers Guardant Health’s Shield Blood Test for Colorectal Cancer Screening

July 01, 2026

From Guardant Health, Inc.

Via Business Wire

Guardant Health Announces FDA Approval of Guardant360 CDx as Companion Diagnostic for Boehringer Ingelheim’s HERNEXEOS®

June 11, 2026

From Guardant Health, Inc.

Via Business Wire

Guardant Health and Collaborators to Present 38 Abstracts Highlighting Breadth and Expanded Clinical Utility of Guardant Liquid Biopsy Tests Powered by InfinityAI at 2026 ASCO Annual Meeting

May 28, 2026

From Guardant Health, Inc.

Via Business Wire

American Cancer Society Recommends Guardant Health’s Shield Blood Test in Updated Colorectal Cancer Screening Guidelines

May 27, 2026

From Guardant Health, Inc.

Via Business Wire

FDA Approves New Guardant360 Liquid CDx, the Largest FDA-Approved Liquid Biopsy Panel with a 100x Expanded Footprint

May 20, 2026

From Guardant Health, Inc.

Via Business Wire

Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 18, 2026

From Guardant Health, Inc.

Via Business Wire

Guardant Health Reports First Quarter 2026 Financial Results and Increases 2026 Revenue Guidance

May 07, 2026

From Guardant Health, Inc.

Via Business Wire

Guardant Health Receives FDA Approval for Guardant360® CDx as a Companion Diagnostic for Arvinas and Pfizer’s VEPPANU (vepdegestrant) for Patients with ER+/HER2- Advanced Breast Cancer with ESR1 Mutations

May 04, 2026

From Guardant Health, Inc.

Via Business Wire

Guardant Health Announces Multi-Year Strategic Collaboration with Nuvalent to Develop Companion Diagnostics and Support Potential Commercialization of Targeted Cancer Therapies Using the Guardant Infinity™ Platform

April 30, 2026

From Guardant Health, Inc.

Via Business Wire

Guardant Health to Participate in Upcoming Investor Conferences

April 29, 2026

From Guardant Health, Inc.

Via Business Wire

Guardant Health to Report First Quarter 2026 Financial Results on May 7, 2026

April 16, 2026

From Guardant Health, Inc.

Via Business Wire

Guardant Health’s InfinityAI Real-World Evidence Supports Approval of ENHERTU® for Previously Treated Patients with HER2-Positive Metastatic Solid Tumors in Japan

March 30, 2026

From Guardant Health, Inc.

Via Business Wire

Guardant Health to Present 28 Abstracts Highlighting Advances in Tumor Typing, Therapy Selection and Expanded Utility of Multiomic Tissue and Liquid Biopsy Testing at AACR 2026

March 18, 2026

From Guardant Health, Inc.

Via Business Wire

Guardant Health Launches Shield Multi-Cancer Detection (MCD) Test in Multiple Markets in Asia with Manulife Partnership

March 16, 2026

From Guardant Health, Inc.

Via Business Wire

New Guardant Health/Harris Poll Survey Shows 92% of All Eligible Americans Believe Colorectal Cancer Blood Tests Should be Accessible and Covered Similar to Medicare

March 13, 2026

From Guardant Health, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.